Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal malignancies and remains largely refractory to immunotherapy because of its profoundly immunosuppressive tumor microenvironment (TME). Emerging advances in cancer neuroscience suggest that immune resistance in PDAC may not be fully explained by immune-cen...
Jia-Long Chen, Yan Du, Ju-Bao Niu et al.· International Immunopharmaco...· 0 citations
Cordycepin exerts antitumor activity in pancreatic cancer by targeting the CDK2/E2F2 axis to suppress malignant progression and by concurrently chemosensitizing cells to gemcitabine, thus holding promise as a therapeutic agent.
Ru He, Yan Du, Wenkai Jiang et al.· Biochemical Pharmacology· 0 citations
In vitro and in vivo experiments demonstrated that GPR87 knockdown inhibits the proliferation, migration, and clonogenic ability of PC cells while promoting their apoptosis, providing preliminary hypothesis-generating insights that require validation in independent institutional or prospective clinical cohorts before a...
Wan-Cheng Li, Dong-Ao Fan, Yan Du et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.